Duke University Clinical and Translational Science Insitute
The Duke Clinical & Translational Science Institute (CTSI) accelerates research by connecting people and resources across Duke University enterprises and beyond. These creative partnerships help generate new knowledge and fuel innovation from discovery to commercialization.
At the NC Research Campus, CTSI’s Translational Population Health Research Group, manages the MURDOCK Study, the Measurement to Understand the Reclassification of Disease of Cabarrus/Kannapolis, The MURDOCK Study is a longitudinal, community-centered population health study that builds upon the promise of precision medicine by linking self-reported health information with data from a variety of -omics platforms housed in the David H. Murdock Research Institute (DHMRI). Duke University created the MURDOCK Study in 2008 with a $35 million gift from David H. Murdock, founder of the NC Research Campus.
Duke investigators and their collaborators harness the power of biomarkers, genomics, and proteomics to analyze nearly 450,000 biological samples from more than 12,000 volunteers who have enrolled in the MURDOCK Study. By identifying genomic linkages across diseases, Duke researchers are developing new ways to treat and prevent disease. Through biobanking, MURDOCK Study samples are available to Duke researchers and their partners. They can evaluate medical histories, demographics, and other descriptors to help better understand diseases that commonly affect public health. Already, the MURDOCK Study is breaking new ground in the understanding of and potential treatments for hepatitis C, osteoarthritis, coronary heart disease, multiple sclerosis, prostate cancer, and other chronic and debilitating diseases.
Duke’s newest study, Project Baseline, was launched in 2017 as a collaboration between Verily, Duke University School of Medicine, Stanford Medicine, and Google. The Project Baseline study is an observational study that will collect, organize, and analyze broad health data from approximately 10,000 participants over the course of at least four years.
The study is designed to develop a well-defined reference, or “baseline,” of good health, as well as a rich data platform that may be used to better understand the transition from health to disease. Participants will join together with a team of experts from across academia, medicine, science, technology, engineering, and design to better understand how health can change over time. Participants will be asked to visit a study site up to four times yearly, test new technologies and wearable devices daily, and participate in interactive surveys and diaries by using a smartphone, computer, or call center. Data collected will include clinical, imaging, self-reported, physical, environmental, behavioral, sensor, molecular, genetic, and other health-related measurements. Biospecimens collected will include blood and saliva, among others. Learn more.
Combining a rich dataset of self-reported health information, banked samples, and Duke thought leadership, the MURDOCK Study is a valuable resource for Duke researchers and their collaborators. Please visit the MURDOCK Study website for more information about opportunities to collaborate with CTSI and Duke-Kannapolis. Visit their webpage on ongoing studies to find out how to enroll in a study.